<?xml version='1.0' encoding='utf-8'?>
<document id="30745518"><sentence text="[Drug properties of fosravuconazole L-lysine ethanolate (NAILIN® Capsules 100 mg), a new oral azole therapeutic for onychomycosis: an analysis based on non-clinical and clinical trial data]."><entity charOffset="20-55" id="DDI-PubMed.30745518.s1.e0" text="fosravuconazole L-lysine ethanolate" /><entity charOffset="94-99" id="DDI-PubMed.30745518.s1.e1" text="azole" /><entity charOffset="30-34" id="DDI-PubMed.30745518.s1.e2" text="azole" /><pair ddi="false" e1="DDI-PubMed.30745518.s1.e0" e2="DDI-PubMed.30745518.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30745518.s1.e0" e2="DDI-PubMed.30745518.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30745518.s1.e0" e2="DDI-PubMed.30745518.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30745518.s1.e2" e2="DDI-PubMed.30745518.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30745518.s1.e2" e2="DDI-PubMed.30745518.s1.e1" /></sentence><sentence text="Ravuconazole is a fourth generation azole exerting strong antifungal activity, with low drug-drug interaction and hepatic dysfunction risks"><entity charOffset="0-12" id="DDI-PubMed.30745518.s2.e0" text="Ravuconazole" /><entity charOffset="36-41" id="DDI-PubMed.30745518.s2.e1" text="azole" /><entity charOffset="7-11" id="DDI-PubMed.30745518.s2.e2" text="azole" /><pair ddi="false" e1="DDI-PubMed.30745518.s2.e0" e2="DDI-PubMed.30745518.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30745518.s2.e0" e2="DDI-PubMed.30745518.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30745518.s2.e0" e2="DDI-PubMed.30745518.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30745518.s2.e2" e2="DDI-PubMed.30745518.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30745518.s2.e2" e2="DDI-PubMed.30745518.s2.e1" /></sentence><sentence text=" Fosravuconazole l-lysine ethanolate (fosravuconazole; NAILIN® Capsules 100 mg) was developed as a ravuconazole prodrug"><entity charOffset="1-36" id="DDI-PubMed.30745518.s3.e0" text="Fosravuconazole l-lysine ethanolate" /><entity charOffset="38-53" id="DDI-PubMed.30745518.s3.e1" text="fosravuconazole" /><entity charOffset="99-111" id="DDI-PubMed.30745518.s3.e2" text="ravuconazole" /><entity charOffset="11-22" id="DDI-PubMed.30745518.s3.e3" text="azole" /><entity charOffset="48-59" id="DDI-PubMed.30745518.s3.e4" text="azole" /><entity charOffset="106-117" id="DDI-PubMed.30745518.s3.e5" text="azole" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e0" e2="DDI-PubMed.30745518.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e0" e2="DDI-PubMed.30745518.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e0" e2="DDI-PubMed.30745518.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e0" e2="DDI-PubMed.30745518.s3.e4" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e0" e2="DDI-PubMed.30745518.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e0" e2="DDI-PubMed.30745518.s3.e5" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e3" e2="DDI-PubMed.30745518.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e3" e2="DDI-PubMed.30745518.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e3" e2="DDI-PubMed.30745518.s3.e4" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e3" e2="DDI-PubMed.30745518.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e3" e2="DDI-PubMed.30745518.s3.e5" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e1" e2="DDI-PubMed.30745518.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e1" e2="DDI-PubMed.30745518.s3.e4" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e1" e2="DDI-PubMed.30745518.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e1" e2="DDI-PubMed.30745518.s3.e5" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e4" e2="DDI-PubMed.30745518.s3.e4" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e4" e2="DDI-PubMed.30745518.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e4" e2="DDI-PubMed.30745518.s3.e5" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e2" e2="DDI-PubMed.30745518.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30745518.s3.e2" e2="DDI-PubMed.30745518.s3.e5" /></sentence><sentence text=" Ravuconazole exerts strong antifungal activity against various pathogenic fungi including dermatophytes and Candida"><entity charOffset="1-13" id="DDI-PubMed.30745518.s4.e0" text="Ravuconazole" /><entity charOffset="8-19" id="DDI-PubMed.30745518.s4.e1" text="azole" /><pair ddi="false" e1="DDI-PubMed.30745518.s4.e0" e2="DDI-PubMed.30745518.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30745518.s4.e0" e2="DDI-PubMed.30745518.s4.e1" /></sentence><sentence text=" Through prodrug formation, pharmacokinetic improvement was achieved, and bioavailability after oral administration reached 100%" /><sentence text=" The plasma ravuconazole concentration became 10-35 times higher than with current oral anti-onychomycosis drugs, and showed good skin and nail tissue transition plus tissue retention"><entity charOffset="12-24" id="DDI-PubMed.30745518.s6.e0" text="ravuconazole" /><entity charOffset="19-30" id="DDI-PubMed.30745518.s6.e1" text="azole" /><pair ddi="false" e1="DDI-PubMed.30745518.s6.e0" e2="DDI-PubMed.30745518.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30745518.s6.e0" e2="DDI-PubMed.30745518.s6.e1" /></sentence><sentence text=" This improvement obtained with fosravuconazole reflects its superior pharmacokinetic properties"><entity charOffset="32-47" id="DDI-PubMed.30745518.s7.e0" text="fosravuconazole" /><entity charOffset="42-56" id="DDI-PubMed.30745518.s7.e1" text="azole" /><pair ddi="false" e1="DDI-PubMed.30745518.s7.e0" e2="DDI-PubMed.30745518.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30745518.s7.e0" e2="DDI-PubMed.30745518.s7.e1" /></sentence><sentence text=" We conducted a clinical trial with fosravuconazole orally administered once a day (100 mg ravuconazole) for 12 weeks in Japanese onychomycosis patients"><entity charOffset="36-51" id="DDI-PubMed.30745518.s8.e0" text="fosravuconazole" /><entity charOffset="91-103" id="DDI-PubMed.30745518.s8.e1" text="ravuconazole" /><entity charOffset="46-57" id="DDI-PubMed.30745518.s8.e2" text="azole" /><entity charOffset="98-109" id="DDI-PubMed.30745518.s8.e3" text="azole" /><pair ddi="false" e1="DDI-PubMed.30745518.s8.e0" e2="DDI-PubMed.30745518.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30745518.s8.e0" e2="DDI-PubMed.30745518.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30745518.s8.e0" e2="DDI-PubMed.30745518.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30745518.s8.e0" e2="DDI-PubMed.30745518.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30745518.s8.e2" e2="DDI-PubMed.30745518.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30745518.s8.e2" e2="DDI-PubMed.30745518.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30745518.s8.e2" e2="DDI-PubMed.30745518.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30745518.s8.e1" e2="DDI-PubMed.30745518.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30745518.s8.e1" e2="DDI-PubMed.30745518.s8.e3" /></sentence><sentence text=" The ravuconazole concentration in nail tissues exceeded the MIC90 against dermatophytes, even after treatment completion"><entity charOffset="5-17" id="DDI-PubMed.30745518.s9.e0" text="ravuconazole" /><entity charOffset="12-23" id="DDI-PubMed.30745518.s9.e1" text="azole" /><pair ddi="false" e1="DDI-PubMed.30745518.s9.e0" e2="DDI-PubMed.30745518.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30745518.s9.e0" e2="DDI-PubMed.30745518.s9.e1" /></sentence><sentence text=" Furthermore, the placebo-controlled, double-blind, comparative trial showed significantly superior effects (at 48 weeks after starting treatment, with a complete cure rate of 59" /><sentence text="4%, a marked clinical improvement rate of 83" /><sentence text="1%, and a mycological cure rate by direct microscopy of 82" /><sentence text="0%)" /><sentence text=" The major adverse reactions were laboratory abnormalities and gastrointestinal disorders with no severe symptoms, suggesting good tolerability" /><sentence text=" Fosravuconazole has fewer drug-drug interactions, is not affected by food, and is also expected to improve medication adherence since the administration period is only 12 weeks and there is no drug-free period as required with pulse therapy"><entity charOffset="1-16" id="DDI-PubMed.30745518.s15.e0" text="Fosravuconazole" /><entity charOffset="11-25" id="DDI-PubMed.30745518.s15.e1" text="azole" /><pair ddi="false" e1="DDI-PubMed.30745518.s15.e0" e2="DDI-PubMed.30745518.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30745518.s15.e0" e2="DDI-PubMed.30745518.s15.e1" /></sentence><sentence text=" Thus, fosravuconazole has many favorable pharmacological properties and can reasonably be expected to become a new oral treatment option for onychomycosis"><entity charOffset="7-22" id="DDI-PubMed.30745518.s16.e0" text="fosravuconazole" /><entity charOffset="17-31" id="DDI-PubMed.30745518.s16.e1" text="azole" /><pair ddi="false" e1="DDI-PubMed.30745518.s16.e0" e2="DDI-PubMed.30745518.s16.e0" /><pair ddi="false" e1="DDI-PubMed.30745518.s16.e0" e2="DDI-PubMed.30745518.s16.e1" /></sentence><sentence text="" /></document>